Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Thematic (Sector/Industry)

United states Health care / Thematic (Sector/Industry)

<ul><li>Biopharma will navigate the uncertainty that comes with the Trump presidency and his alliance with a populist healthcare agenda, but the less regulation-minded Republicans should be good for the group, reducing scrutiny on M&amp;A and drug prices.</li><li>We highlight five biopharma themes and trends heading into 2025.</li><li>Less FTC scrutiny should drive biopharma M&amp;A. Biopharma M&amp;A has meaningfully slowed since mid-year, adding eight deals at &gt;$50MM after the LLY-MORF acquisition in early July, which brings the YTD total to 34 and no longer on pace to exceed 2022 (43 deals) or 2023 (38 deals).</li></ul>

Biopharma will navigate the uncertainty that comes with the Trump presidency and his alliance with a populist healthcare agenda, but the less regulation-minded Republicans should be good for the group, reducing scrutiny on M&amp;A and drug prices.We highlight five biopharma themes and trends heading into 2025.Less FTC scrutiny should drive biopharma M&amp;A. Biopharma M&amp;A has meaningfully slowed since mid-year, adding eight deals at &gt;$50MM after the LLY-MORF acquisition in early July, which brings the YTD total to 34 and no longer on pace to exceed 2022 (43 deals) or 2023 (38 deals).

Five Biopharma Trends for 2025 - November 13, 2024